This is an application for the conduct of cancer clinical research activities as a member institution of the Southwest Oncology Group (SWOG).
The specific aims are: 1) to conduct single and multidisciplinary clinical trials as sponsored by SWOG; 2) to recruit large numbers of patients to cooperative group clinical trials with an emphasis on the inclusion of women and minorities populations; 3) to conduct institutional pilot trials as potential group trials; 4) to expand the Cooperative Group Outreach Program (CGOP) as supported by this member institution; 5) to educate health care professionals as to the methods and procedures involved in the conduct of cancer clinical trials; 6) to participate in the administrative and scientific activities of SWOG; 7) to support a data management system which provides for high quality and timely data submission. These activities are supported through the interdisciplinary efforts of individuals within the Division of Hematology/Oncology and the Departments of Surgery, Radiation Oncology, Urology, Cytogenetics, Pathology, Diagnostic Radiology, Pulmonary Medicine, Otolaryngology, Gastroenterology and Neurosurgery. Our team of high trained research nurses and clinical research associates work directly with our physician investigators to assure a high level of patient eligibility and the generation of accurate and timely data for each human subject enrolled. Likewise, this staff brings the identical attention to each of our CGOP affiliate institutions to assist each in developing and achieving good clinical practices in the conduct of cooperative group clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA058416-06
Application #
2441663
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
1993-05-01
Project End
2002-12-31
Budget Start
1998-03-30
Budget End
1998-12-31
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Henry Ford Health System
Department
Type
Schools of Medicine
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 139 publications